NSCLC large cell and adenocarcinoma patients should be tested at diagnosis for EGFR mutations as those who exhibit such mutations benefit from EGFR inhibitors (e.g. erlotinib or gefitinib) in the first-line setting, as recommended by NCCN guidelines [13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.